Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: An open-label, three-group, randomised controlled superiority trial

The Lancet

Volumn 386, Issue 10012, 2015, Pages 2507-2519

  Desai, Meghna ^a   Gutman, Julie ^a   L'Lanziva, Anne ^a   Otieno, Kephas ^c   Juma, Elizabeth ^c   Kariuki, Simon ^c   Ouma, Peter ^c   Were, Vincent ^c   Laserson, Kayla ^a   Katana, Abraham ^b   Williamson, John ^a   Ter Kuile, Feiko O ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Centers for Disease Control and Prevention Kenya   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PIPERAQUINE; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HISTOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MICROSCOPY; OPEN STUDY; OUTCOME ASSESSMENT; PARASITE INCIDENCE; PARASITEMIA; PREGNANCY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; MASS SCREENING; MULTICENTER STUDY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL DIAGNOSIS; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KENYA; MALARIA; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL DIAGNOSIS; PYRIMETHAMINE; QUINOLINES; RISK FACTORS; SULFADOXINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960374899     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00310-4     Document Type: Article

References (32)

1. S Dellicour, AJ Tatem, CA Guerra, RW Snow, FO ter Kuile Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study PLoS Med 7 2010 e1000221
2. M Desai, FO ter Kuile, F Nosten et al. Epidemiology and burden of malaria in pregnancy Lancet Infect Dis 7 2007 93 104
3. PG Walker, FO ter Kuile, T Garske, C Menendez, AC Ghani Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study Lancet Glob Health 2 2014 e460 e467
4. WHO A strategic framework for malaria prevention and control during pregnancy in the African region 2004 WHO Regional Office for Africa Brazzaville
5. TP Eisele, DA Larsen, PA Anglewicz et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa Lancet Infect Dis 12 2012 942 949
6. RM Chico, J Cano, C Ariti et al. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis Trop Med Int Health 2015 10.1111/tmi.12595 published online Sept 1.
7. M Alifrangis, S Nag, ML Schousboe et al. Independent origin of Plasmodium falciparum antifolate super-resistance, Uganda, Tanzania and Ethiopia Emerg Infect Dis 20 2014 1280 1286
8. WE Harrington, TK Mutabingwa, A Muehlenbachs et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment Proc Natl Acad Sci USA 106 2009 9027 9032
9. J Gutman, L Kalilani, S Taylor et al. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthetase reduces the effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women J Infect Dis 211 2015 1997 2005
10. RD Newman, ME Parise, L Slutsker, B Nahlen, RW Steketee Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa Trop Med Int Health 8 2003 488 506
11. CA Clerk, J Bruce, PK Affipunguh et al. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana J Infect Dis 198 2008 1202 1211
12. R Gonzalez, M Desai, E Macete et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial PLoS Med 11 2014 e1001735
13. R Gonzalez, G Mombo-Ngoma, S Ouedraogo et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial PLoS Med 11 2014 e1001733
14. V Briand, J Bottero, H Noel et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine J Infect Dis 200 2009 991 1001
15. RS Chandra, J Orazem, D Ubben, S Duparc, J Robbins, P Vandenbroucke Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa Malar J 12 2013 122
16. Kimani J, Phiri K, Kamiza S, et al. Azithromycin/chloroquine (AZCQ) versus sulfadoxine/pyrimethamine (SP) in intermittent preventive treatment of falciparum malaria infection in pregnant women (IPTp) in sub-Saharan Africa: an open-label randomized trial. European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark; April 25-28, 2015. EP168.
17. M Nambozi, M Mulenga, T Halidou et al. Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial Reprod Health 12 2015 5
18. WHO Guidelines for the treatment of malaria 2015 World Health Organization Geneva
19. H Tagbor, J Bruce, M Agbo, B Greenwood, D Chandramohan Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial PLoS One 5 2010 e14425
20. H Tagbor, M Cairns, K Bojang et al. A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy PLoS One 10 2015 e0132247
21. JL Ballard, JC Khoury, K Wedig, L Wang, BL Eilers-Walsman, R Lipp New Ballard Score, expanded to include extremely premature infants J Pediatr 119 1991 417 423
22. C Schmiegelow, T Scheike, M Oesterholt et al. Development of a fetal weight chart using serial trans-abdominal ultrasound in an East African population: a longitudinal observational study PLoS One 7 2012 e44773
23. I Naidoo, C Roper Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria Trends Parasitol 29 2013 505 515
24. WHO WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) 2013 World Health Organization Geneva
25. KM Lwin, AP Phyo, J Tarning et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria Antimicrob Agents Chemother 56 2012 1571 1577
26. K Kayentao, P Garner, AM van Eijk et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis JAMA 309 2013 594 604
27. M Capan, G Mombo-Ngoma, A Makristathis, M Ramharter Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin Malar J 9 2010 303
28. RM Chico, BB Hack, MJ Newport, E Ngulube, D Chandramohan On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections Expert Rev Anti Infect Ther 11 2013 1303 1332
29. RM Chico, P Mayaud, C Ariti, D Mabey, C Ronsmans, D Chandramohan Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review JAMA 307 2012 2079 2086
30. FIND TDR WHO CDC Malaria rapid diagnostic test performance. Results of WHO product testing of malaria RDTs: round 4 (2012) 2012 World Health Organization Italy
31. V Bigira, J Kapisi, TD Clark et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial PLoS Med 11 2014 e1001689
32. JM Benjamin, BR Moore, S Salman et al. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women Antimicrob Agents Chemother 59 2015 4260 4271